Matthew Doctor
CIK 1844838 · View on SEC EDGAR ↗
First SEC filing: Feb. 9, 2021 · Latest: Feb. 9, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 22, 2024 | RGS | A | 16,500 | — | — | 19,584 Direct | +535.02% | Acquired | (price as of 2026-08-21) |
| Nov. 5, 2024 | RGS | F | 547 | $23.37 | $12,783 | 3,084 Direct | -15.06% | Disposed | 13.4% (price as of 2026-08-21) |
| Nov. 5, 2024 | RGS | F | 339 | $23.37 | $7,922 | 3,292 Direct | -9.34% | Disposed | 13.4% (price as of 2026-08-21) |
| Feb. 8, 2024 | RGS | F | 211 | $12.35 | $2,606 | 76,671 Direct | -0.27% | Disposed | 114.7% (price as of 2026-08-21) |
| Nov. 6, 2023 | RGS | F | 3,648 | $0.53 | $1,933 | 76,882 Direct | -4.53% | Disposed | 150.1% (price as of 2026-08-21) |
| Nov. 7, 2022 | RGS | F | 2,837 | $1.26 | $3,575 | 80,530 Direct | -3.40% | Disposed | 5.2% (price as of 2026-08-21) |
| May 5, 2022 | RGS | A | 875,000 | — | — | 875,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 8, 2022 | RGS | F | 4,343 | $1.65 | $7,166 | 83,367 Direct | -4.95% | Disposed | -19.7% (price as of 2026-08-21) |
| Nov. 5, 2021 | RGS | A | 46,344 | — | — | 87,710 Direct | +112.03% | Acquired | (price as of 2026-08-21) |
| Nov. 5, 2021 | RGS | A | 112,500 | — | — | 112,500 Direct | — | Acquired | (price as of 2026-08-21) |
| Nov. 5, 2021 | RGS | A | 112,500 | — | — | 112,500 Direct | — | Acquired | (price as of 2026-08-21) |
| Nov. 5, 2021 | RGS | A | 34,758 | — | — | 76,124 Direct | +84.03% | Acquired | (price as of 2026-08-21) |
| Nov. 5, 2021 | RGS | A | 12,234 | $2.76 | $33,766 | 41,366 Direct | +42.00% | Acquired | -52.0% (price as of 2026-08-21) |
| Feb. 8, 2021 | RGS | A | 28,382 | — | — | 29,132 Direct | +3784.27% | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| May 5, 2022 | RGS | Stock Options | Common Stock (875,000) | $1.26 | May 5, 2032 | 875,000 | Acquired |
| Nov. 5, 2021 | RGS | Stock Appreciation Rights | Common Stock (112,500) | $2.76 | Nov. 5, 2031 | 112,500 | Acquired |
| Nov. 5, 2021 | RGS | Stock Options | Common Stock (112,500) | $2.76 | Nov. 5, 2031 | 112,500 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 9, 2021 | RGS | Common Stock | 750 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
RGS
CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $371,250 | — | $570,000 | — | $45,555 | $1,586,805 |
| 2023 | — | — | — | — | $1,041,000 | — | $38,862 | $1,938,862 |
| 2022 | — | — | $127,909 | $1,022,500 | $242,990 | — | $1,375 | $1,943,921 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.